Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5183348 | 0.99 | ADRA2C (0.47) | ADRA2CSLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL3327849 | 0.90 | ADRA2C (0.51) | ADRA2CSLC6A2SLC6A4SLC6A3HTR2A | |
| Hydrochloric Acid SCHEMBL5184649 | 0.89 | ADRA2C (0.50) | ADRA2CSLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL3329614 | 0.89 | SLC6A2 (0.48) | ADRA2CSLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL5184692 | 0.85 | ADRA2C (0.46) | ADRA2CSLC6A2SLC6A4SLC6A3HTR2A | |
| Hydrochloric Acid SCHEMBL3329665 | 0.84 | ADRA2C (0.45) | ADRA2CSLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL5184207 | 0.84 | ADRA2C (0.49) | ADRA2CSLC6A2SLC6A4SLC6A3HTR2A | |
| Hydrochloric Acid SCHEMBL3328333 | 0.82 | ADRA2C (0.45) | ADRA2CSLC6A2SLC6A4SLC6A3HTR2A | |
| Hydrochloric Acid SCHEMBL3329410 | 0.80 | ADRA2C (0.47) | ADRA2CSLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL1552471 | 0.78 | ADRA2C (0.67) | ADRA2CSLC6A2SLC6A4SLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| US-20050250775-A1 | Novel compounds | FISH PAUL V | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250775-A1 | Novel compounds | OPRL1, UGT1A1, NPSR1 | ADRA2C 66/4885SLC6A2 133/4885SLC6A4 114/4885 |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | OPRL1, MYLK2, TNNT2 | ADRA2C 54/4885SLC6A2 201/4885SLC6A4 350/4885 |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | ADRA2C 43/4885SLC6A2 109/4885SLC6A4 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.